XOMA
Xoma Royalty Corporation
NASDAQ · Biotechnology
$24.86
-0.06 (-0.24%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.07M | 45.56M | 48.20M |
| Net Income | -2,126,496 | -2,452,418 | -2,537,562 |
| EPS | — | — | — |
| Profit Margin | -4.7% | -5.4% | -5.3% |
| Rev Growth | -2.0% | +14.7% | +11.9% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 93.18M | 89.27M | 94.75M |
| Total Equity | 252.44M | 241.93M | 256.04M |
| D/E Ratio | 0.37 | 0.37 | 0.37 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -3,149,560 | -2,902,540 | -2,951,728 |
| Free Cash Flow | -1,725,404 | -1,967,070 | -1,836,225 |